DeutschNewstral
Article
Mmarketwatch.com on 2017-11-09 13:13
Sage Therapeutics stock surges 50% on positive trial results in postpartum depression
Related news
Sage Therapeutics surges on postpartum depression drug studywkrg.com- MSage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial resultsmarketwatch.com
- MSage Therapeutics shares surge 45% on positive trail of postpartum depression drugmarketwatch.com
Sage Therapeutics to seek approval of postpartum depression drug after trial winbizjournals.com- Sage Therapeutics asks FDA to approve lead drug for postpartum depressionbizjournals.com
New Drug Eases Postpartum Depression In Victory For Tiny Sage TherapeuticsForbes- MSage Therapeutics stock bounces 49% after positive results for depression treatmentmarketwatch.com
Hayden Panettiere Receiving Treatment For Postpartum Depressionhuffingtonpost.com- BSage Stock Rises on Postpartum Depression Drug Data3 min readbarrons.com
SCR11: Legislator aims to create postpartum depression awarenessuniverse.byu.edu- IHere’s why Sage Therapeutics fell 18% on Tuesday morninginvezz.com
Postpartum depressionArkansas Online- Pill for postpartum depression by Cambridge's Sage succeeds in late-stage trialbizjournals.com
- MSage jumps 8% on expedited development plan for postpartum depression treatmentmarketwatch.com
- A Drug For Postpartum Depression? Sage Passes Early Test With Experimental TreatmentForbes
- Eyeing FDA approval, Sage lays out strategy for dual postpartum depression drugsbizjournals.com
- MFast-acting treatment for postpartum depression, if approved, could help hundreds of thousands of new mothersmarketwatch.com
- BSage Therapeutics Is Cratering Because Its Depression Treatment Failed In A Key Trialbarrons.com
- MSage Therapeutics shares halted ahead of regulatory meeting on post-partum treatmentmarketwatch.com